Last reviewed 2026-04-20 · How we verify

Euprax (ALBUTOIN)

Phase 2 active Small molecule

Euprax (generic name: ALBUTOIN) is a albutoin drug. It is currently in Phase 2 development.

Euprax works by interacting with specific biological pathways to produce its therapeutic effects.

Euprax, also known as Albutoin, is a small molecule drug in the albutoin class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain physiological processes. Euprax is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unclear. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand the properties and potential uses of Euprax.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ALBUTOIN
Drug class	albutoin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's physiological processes as a complex orchestra. Euprax is like a conductor that helps the different parts of the orchestra work together in harmony, leading to a desired outcome. By modulating these processes, Euprax can help alleviate certain symptoms or conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Euprax CI brief — competitive landscape report
Euprax updates RSS · CI watch RSS

Frequently asked questions about Euprax

What is Euprax?

Euprax (ALBUTOIN) is a albutoin drug.

How does Euprax work?

Euprax works by interacting with specific biological pathways to produce its therapeutic effects.

What is the generic name of Euprax?

ALBUTOIN is the generic (nonproprietary) name of Euprax.

What drug class is Euprax in?

Euprax belongs to the albutoin class. See all albutoin drugs at /class/albutoin.

What development phase is Euprax in?

Euprax is in Phase 2.

Drug class: All albutoin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing